Home / Tag Archives: immunotherapy

Tag Archives: immunotherapy

The Treatment Stopped—Did the Benefit Last? New Baricitinib Data in Type 1 Diabetes

Baricitinib type 1 diabetes research concept showing beta-cell preservation and follow-up after treatment ends.

New follow-up research on baricitinib for type 1 diabetes addresses a crucial question: what happens after the drug is stopped? The original BANDIT trial showed that 48 weeks of oral baricitinib helped preserve beta-cell function in people with recently diagnosed type 1 diabetes. However, new follow-up research examines participants through …

Read More »

The First Disease-Modifying Treatment After a Type 1 Diabetes Diagnosis: Why Teplizumab Is Changing the Conversation

Pediatric endocrinologist discussing teplizumab treatment options with a family following a new type 1 diabetes diagnosis.

For decades, treatment after a type 1 diabetes diagnosis focused almost entirely on insulin replacement and blood glucose management. While advances in technology have improved care, clinicians have had few ways to address the autoimmune process driving beta-cell loss. That is beginning to change. With the FDA’s expansion of teplizumab-mzwv …

Read More »

Delaying Type 1 Diabetes Progression: What Long-Term Data Mean for Screening and Intervention

Immunotherapy vial with diabetes monitoring tools illustrating type 1 diabetes prevention and early intervention research

Can a chronic condition like type 1 diabetes be slowed before it fully develops? Recent long-term studies suggest that preventing or delaying type 1 diabetes may be closer to reality than once believed. In fact, emerging immunotherapy data is changing how clinicians view early-stage disease and the opportunity to intervene …

Read More »